Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 47.4139
- Book/Share 73.5163
- PB 6.5429
- Debt/Equity 0.208
- CurrentRatio 2.9009
- ROIC 0.1625
- MktCap 122176540000.0
- FreeCF/Share 12.579
- PFCF 38.2543
- PE 30.8936
- Debt/Assets 0.1485
- DivYield 0
- ROE 0.227
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VRTX | Oppenheimer | Perform | Outperform | -- | $540 | Feb. 13, 2026 |
| Resumed | VRTX | Barclays | -- | Overweight | -- | $606 | Jan. 28, 2026 |
| Upgrade | VRTX | RBC Capital Mkts | Sector Perform | Outperform | -- | $546 | Jan. 22, 2026 |
| Upgrade | VRTX | Bernstein | Market Perform | Outperform | -- | -- | Jan. 12, 2026 |
| Resumed | VRTX | UBS | -- | Buy | -- | $535 | Jan. 7, 2026 |
| Upgrade | VRTX | Wolfe Research | Peer Perform | Outperform | -- | $548 | Jan. 6, 2026 |
| Upgrade | VRTX | Morgan Stanley | Equal Weight | Overweight | -- | $516 | Dec. 3, 2025 |
| Initiation | VRTX | Scotiabank | -- | Sector Outperform | -- | $495 | Nov. 13, 2025 |
| Upgrade | VRTX | Leerink Partners | Market Perform | Outperform | -- | $456 | Sept. 25, 2025 |
| Initiation | VRTX | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
News
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Office Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Jessica Fye - JPMorgan Geoff Meacham - Citibank Michael Yee - Jefferies William Pickering - Bernstein Liisa Bayko - Evercore ISI Phil Nadeau - TD Cowen Eliana Merle - UBS Tazeen Ahmad - Bank of America Dave Risinger - Leerink …
Read More
Markets Steady, Positive; Q4 Earnings Keep Rolling
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Indexes mostly shrugged off +25% steel tariffs announced by President Trump; VRTX, LSCC report for Q4.
Read More
Vertex's Revenue Surges but EPS Slips
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion.
Read More
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Published: February 10, 2025 by: Investopedia
Sentiment: Positive
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani
- Employees 6100